The Renal Denervation Buzz: Separating Fact From Myth
This article was originally published in The Gray Sheet
Executive Summary
Is renal denervation the next blockbuster device technology? Judging by the excitement at the EuroPCR meeting in May, the potential is there. Just before the meeting, Covidien announced its acquisition of renal denervation start-up Maya Medical.
You may also be interested in...
Covidien Quits Renal Denervation Race; Others Stick It Out, For Now
A Covidien executive said in an interview that the firm’s decision to halt development of its OneShot renal denervation system was made prior to Medtronic’s recent announcement that its Symplicity device missed its endpoint. Covidien cites slower-than-expected development of the renal denervation market.
Symplicity Makes Life Difficult For Renal Denervation Programs
A big slice of the device industry, from large-cap firms to venture capitalists, is trying to understand the new reality in the wake of Medtronic’s announcement that its Symplicity hypertension trial missed its endpoint
People Briefs: New CEO At DFINE; CMS Departure; FDA Seeks CIO
DFINE taps new president and CEO. CMS Program Integrity chief Peter Budetti steps down. FDA searching for new chief information officer. More personnel announcements from Endo Health Solution, STAAR Surgical and Solulink.